Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Biliary Tract Diseases

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 124 articles: HTML format

Single Articles

May 2023
1. TOMLINSON JL, Valle JW, Ilyas SI
   Immunobiology of Cholangiocarcinoma.
   J Hepatol. 2023 May 16:S0168-8278(23)00338-0. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
2. BOLDUAN F, Geisel D, Pahl S, Wree A, et al
   Painless jaundice with segmental obstructive cholestasis.
   J Hepatol. 2023 May 9:S0168-8278(23)00209-X. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   April 2023
3. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
   The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
   J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
4. DANA J, Debray D, Vilgrain V
   Reply to: "The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience".
   J Hepatol. 2023 Apr 10:S0168-8278(23)00222-2. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
5. FICKERT P, Lin AC, Ritschl H, Hammer N, et al
   Portal venous branches as an anatomic railroad for a gut-bile duct-axis.
   J Hepatol. 2023 Apr 10:S0168-8278(23)00221-0. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   March 2023
6. 
   EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
   J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
7. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
   Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
   J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
8. JUANOLA A, Moreta MJ, Caballero G, Diaz A, et al
   Fever and cholestasis in a male.
   J Hepatol. 2023;78:e90-e92.
   PubMed    
   
   
   
9. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
   Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
   J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   February 2023
10. CALVO PL, Giugliano L, Evangelista A, Bignamini E, et al
    The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience.
    J Hepatol. 2023 Feb 17:S0168-8278(23)00094-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
11. CADAMURO M, Al-Taee A, Gonda TA
    Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma.
    J Hepatol. 2023 Feb 3:S0168-8278(23)00080-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
12. DUWE L, Munoz-Garrido P, Lewinska M, Lafuente-Barquero J, et al
    MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
    J Hepatol. 2023;78:364-375.
    PubMed     Abstract available
    
    
    January 2023
13. SPOSITO C, Cucchetti A, Mazzaferro V
    Survival Benefit Of Lymphadenectomy For Intrahepatic Cholangiocarcinoma: It Might Be Gold Even If It Does Not Glitter.
    J Hepatol. 2023 Jan 31:S0168-8278(23)00073-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
14. JI R, Chen J, Xie Y, Dou X, et al
    Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00015-6. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
15. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581].
    J Hepatol. 2023 Jan 11:S0168-8278(22)03321-9. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
16. MAGYAR CTJ, Beldi G, Banz V
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma - Letter to the editor.
    J Hepatol. 2023 Jan 5:S0168-8278(22)03474-2. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    December 2022
17. KOERKAMP BG, Clavien PA, Polak WG
    Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?
    J Hepatol. 2022 Dec 23:S0168-8278(22)03327-X. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
18. HARTMANN P, Schnabl B
    Fungal infections and the fungal microbiome in hepatobiliary disorders.
    J Hepatol. 2022 Dec 21:S0168-8278(22)03415-8. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
19. KENDRE G, Murugesan K, Brummer T, Segatto O, et al
    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    November 2022
20. VILLARD C, Friis-Liby I, Rorsman F, Said K, et al
    Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03303-7. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
21. MERTERS J, Lamarca A
    Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03296.
    PubMed     Abstract available
    
    
    October 2022
22. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    PubMed     Abstract available
    
    
    
23. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    PubMed     Abstract available
    
    
    
24. OKAWA Y, Iwasaki Y, Johnson TA, Ebata N, et al
    Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03137.
    PubMed     Abstract available
    
    
    
25. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    
    
    
    September 2022
26. CONBOY CB, Yonkus JA, Buckarma EH, Mun DG, et al
    LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
    J Hepatol. 2022 Sep 23. pii: S0168-8278(22)03121.
    PubMed     Abstract available
    
    
    
27. HARDING JJ, Khalil DN, Fabris L, Abou-Alfa GK, et al
    Rational Development of Combination Therapies in Biliary Tract Cancers.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03078.
    PubMed     Abstract available
    
    
    
28. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    PubMed    
    
    
    
29. BJORKSTROM NK
    Immunobiology of the biliary tract system.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03020.
    PubMed     Abstract available
    
    
    August 2022
30. ZHANG R, Huang J, Shan J, Chen Y, et al
    Peripheral blood CD177(+) cells as an early diagnostic marker for biliary atresia: a prospective multicentre study in pediatric patients with cholestasis.
    J Hepatol. 2022 Aug 19. pii: S0168-8278(22)03005.
    PubMed    
    
    
    
31. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    PubMed     Abstract available
    
    
    
32. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    PubMed     Abstract available
    
    
    
33. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    PubMed     Abstract available
    
    
    
34. VITHAYATHIL M, Khan SA
    Current epidemiology of cholangiocarcinoma in western countries.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02988.
    PubMed     Abstract available
    
    
    
35. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    PubMed    
    
    
    July 2022
36. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    
    
    
    
37. ZHANG R, Su L, Fu M, Wang Z, et al
    CD177(+) cells produce neutrophil extracellular traps to promote biliary atresia.
    J Hepatol. 2022 Jul 5. pii: S0168-8278(22)00409.
    PubMed     Abstract available
    
    
    
38. MULLER AL, Casar C, Preti M, Krzikalla D, et al
    Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02923.
    PubMed     Abstract available
    
    
    June 2022
39. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed     Abstract available
    
    
    
40. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed     Abstract available
    
    
    
41. LABIANO I, Agirre-Lizaso A, Olaizola P, Echebarria A, et al
    TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
    J Hepatol. 2022 Jun 21. pii: S0168-8278(22)00372.
    PubMed     Abstract available
    
    
    
42. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available
    
    
    
43. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    
    
    
    
44. HOGDALL D, O'Rourke CJ, Larsen FO, Zarforoushan S, et al
    Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00358.
    PubMed     Abstract available
    
    
    
45. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    
    
    
    
46. SCHLEGEL A, Porte R, Dutkowski P
    Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy.
    J Hepatol. 2022;76:1330-1347.
    PubMed     Abstract available
    
    
    May 2022
47. 
    EASL Clinical Practice Guidelines on Sclerosing Cholangitis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00326.
    PubMed    
    
    
    
48. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed    
    
    
    
49. RAGGI C, Taddei ML, Rae C, Braconi C, et al
    Metabolic Reprogramming in Cholangiocarcinoma.
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00314.
    PubMed     Abstract available
    
    
    
50. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    
    
    
    April 2022
51. LUDDE T, Boulter L
    Joining the dots - NEDDylation in cancer cells regulates the tumour environment in Cholangiocarcinoma.
    J Hepatol. 2022 Apr 28. pii: S0168-8278(22)00253.
    PubMed    
    
    
    March 2022
52. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    PubMed     Abstract available
    
    
    
53. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available
    
    
    
54. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    
    
    
    February 2022
55. OLAIZOLA P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, et al
    Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00082.
    PubMed     Abstract available
    
    
    
56. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available
    
    
    January 2022
57. CASOLINO R, Amato F, Rae C, Puttagunta S, et al
    Receptor Tyrosine kinase co-amplification and benefit from HER2 inhibitors in Biliary Tract Cancers.
    J Hepatol. 2022 Jan 27. pii: S0168-8278(22)00025.
    PubMed    
    
    
    December 2021
58. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available
    
    
    
59. IZQUIERDO-SANCHEZ L, Lamarca A, La Casta A, Buettner S, et al
    Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02252.
    PubMed     Abstract available
    
    
    
60. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    
    
    
    November 2021
61. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available
    
    
    October 2021
62. HERTA T, Kersten R, Chang JC, Hubers L, et al
    Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection.
    J Hepatol. 2021 Oct 27. pii: S0168-8278(21)02116.
    PubMed     Abstract available
    
    
    
63. KEPPLER D, Beuers U, Trauner M
    A life with bile acids: Alan F. Hofmann (1931-2021).
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02081.
    PubMed    
    
    
    
64. LOUIS C, Coulouarn C
    One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/beta-catenin pathways in cholangiocarcinoma.
    J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02108.
    PubMed    
    
    
    
65. MALLET V
    Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".
    J Hepatol. 2021;75:990-992.
    PubMed    
    
    
    September 2021
66. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available
    
    
    
67. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available
    
    
    August 2021
68. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
    PubMed    
    
    
    
69. DE JONG IEM, van den Heuvel MC, Wells RG, Porte RJ, et al
    The heterogeneity of the biliary tree.
    J Hepatol. 2021 Aug 19. pii: S0168-8278(21)00251.
    PubMed    
    
    
    July 2021
70. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available
    
    
    
71. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
    PubMed    
    
    
    
72. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    
    
    
    June 2021
73. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available
    
    
    
74. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    
    
    
    
75. ZHANG Y, Zuo C, Liu L, Hu Y, et al
    Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
    PubMed     Abstract available
    
    
    
76. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    
    
    
    
77. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    PubMed     Abstract available
    
    
    May 2021
78. SONG X, Xu H, Wang P, Wang J, et al
    Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
    PubMed     Abstract available
    
    
    
79. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available
    
    
    
80. BOULTER L, Ebrahimkhani MR
    Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
    J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.
    PubMed    
    
    
    
81. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    
    
    
    
82. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available
    
    
    April 2021
83. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available
    
    
    
84. REICH M, Spomer L, Klindt C, Fuchs K, et al
    Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
    PubMed     Abstract available
    
    
    
85. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
    FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
    J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
    PubMed     Abstract available
    
    
    March 2021
86. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available
    
    
    
87. DELTENRE P, Moreno C, Trepo E
    Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
    J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.
    PubMed    
    
    
    
88. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available
    
    
    
89. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
    FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
    PubMed     Abstract available
    
    
    
90. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    PubMed     Abstract available
    
    
    February 2021
91. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    
    
    
    
92. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    
    
    
    
93. BOYER JL, Soroka CJ
    Bile formation and Secretion: An update.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
    PubMed     Abstract available
    
    
    
94. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    
    
    
    
95. CASOLINO R, Braconi C
    CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.
    PubMed    
    
    
    
96. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    
    
    
    
97. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
    Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
    J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.
    PubMed    
    
    
    
98. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    
    
    
    
99. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available
    
    
    
100. BEAUFRERE A, Calderaro J, Paradis V
     Combined hepatocellular-cholangiocarcinoma: An update.
     J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
     PubMed     Abstract available
     
     
     January 2021
101. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
     STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
     J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
     PubMed     Abstract available
     
     
     
102. JAVITT NB
     Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
     J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
     PubMed    
     
     
     
103. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
     A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
     J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
     PubMed     Abstract available
     
     
     
104. RAGGI C, Taddei ML, Sacco E, Navari N, et al
     Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
     J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
     PubMed     Abstract available
     
     
     
105. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
     Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
     J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
     PubMed     Abstract available
     
     
     
106. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
     Challenges in understanding the consequences of variants in ABCB4 gene.
     J Hepatol. 2021;74:242-243.
     PubMed    
     
     
     
107. STATTERMAYER AF, Ferenci P, Trauner M
     Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
     J Hepatol. 2021;74:244-245.
     PubMed    
     
     
     December 2020
108. SARKAR M, Grab J, Irani RA
     Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
     J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
     PubMed    
     
     
     
109. PHILLIPS J, Senaratne S
     Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
     J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
     PubMed    
     
     
     
110. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
     Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
     PubMed     Abstract available
     
     
     
111. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
     CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
     PubMed     Abstract available
     
     
     
112. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
     Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
     PubMed     Abstract available
     
     
     November 2020
113. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
     TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
     J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
     PubMed     Abstract available
     
     
     
114. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
     Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
     J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
     PubMed     Abstract available
     
     
     
115. STEIN S, Henze L, Poch T, Carambia A, et al
     IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
     J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
     PubMed     Abstract available
     
     
     October 2020
116. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
     Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
     J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
     PubMed     Abstract available
     
     
     
117. CARBONE M, Ronca V, Invernizzi P
     Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
     J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
     PubMed    
     
     
     
118. HYDES T, Khakoo SI
     A spotlight on natural killer cells in primary biliary cholangitis.
     J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
     PubMed    
     
     
     
119. CAI SY, Yu D, Soroka CJ, Wang J, et al
     Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
     J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
     PubMed     Abstract available
     
     
     September 2020
120. DYSON JK, Jones DEJ
     UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
     J Hepatol. 2020;73:499-501.
     PubMed    
     
     
     July 2020
121. TRAUNER M
     Effective medical treatments for PSC needed ASAP - is AESOP the answer?
     J Hepatol. 2020;73:12-14.
     PubMed    
     
     
     June 2020
122. HARMS MH, van Buuren HR, van der Meer AJ
     Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
     J Hepatol. 2020;72:1211-1212.
     PubMed    
     
     
     
123. CORPECHOT C, Rousseau A, Chazouilleres O
     Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
     J Hepatol. 2020;72:1210-1211.
     PubMed    
     
     
     April 2020
124. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
     Liver-related mortality is similar among men and women with cirrhosis.
     J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: